Indeed, if the company can maintain 25% qoq growth then we should have >30M in adapt revenues in CY2019.
The biggest issue for me is that they haven't been able to consistently show adapt growth at the rate it needs to be, this quarter had been much better than the previous tho, and the expenses growth is just out of control.
Adapt Revenue:
Q317 - 1900 (6%)
Q417 - 2100 (11%)
Q118 - 2200 (5%)
Q218 - 2700 (23%)
Expenses:
Q317 - 8,913.00
Q417 - 10,789.00 (21%)
Q118 - 11,571.00 (7%)
Q218 - 13,885.00 (20%)
They company need to stabilise the expenses while maintaining the adapt revenue increases, which I think we are yet to see (code red resulted in adapt revenues decreasing). It is a shame there is an extra $1m in R&D expenses this quarter and an extra $1m in staff expenses otherwise the expense growth would have been fairly stable.
What ever happened to getting a TAVR partner in Q1?
Ann: Voluntary Suspension, page-119
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M | |||
| Open | High | Low | Value | Volume |
| $18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 247 | 2 |
View Market Depth
| Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |